Monday, January 15, 2018 -- Researchers at Western University believe they have found a common link between the degenerative brain condition CTE, and a variant of ALS, or Lou Gehrig’s disease.
Thursday, January 11, 2018 -- BACKGROUND AND PURPOSE: There is an emerging need for biomarkers to better categorize clinical phenotypes and predict progression in amyotrophic lateral sclerosis. This study aimed to quantify cervical spinal gray matter atrophy in amyotrophic lateral sclerosis and investigate its association with clinical disability at baseline and after 1 year. MATERIALS AND METHODS: Twenty-nine patients with amyotrophic lateral sclerosis and 22 healthy controls were scanned with 3T MR imaging. Standard functional scale was recorded at the time of MR imaging and after 1 year. MR imaging data were processed automatically to measure the spinal cord, gray matter, and white matter cross-sectional areas. A statistical analysis assessed the difference in cross-sectional areas between patients with amyotrophic lateral sclerosis and controls, correlations
Thursday, January 11, 2018 -- BACKGROUND AND PURPOSE: Amyotrophic lateral sclerosis is a neurodegenerative disease involving the upper and lower motor neurons. In amyotrophic lateral sclerosis, pathologic changes in the primary motor cortex include Betz cell depletion and the presence of reactive iron-loaded microglia, detectable on 7T MR images as atrophy and T2*-hypointensity. Our purposes were the following: 1) to investigate the signal hypointensity-to-thickness ratio of the primary motor cortex as a radiologic marker of upper motor neuron involvement in amyotrophic lateral sclerosis with a semiautomated method at 3T, 2) to compare 3T and 7T results, and 3) to evaluate whether semiautomated measurement outperforms visual image assessment. MATERIALS AND METHODS: We investigated 27 patients and 13 healthy subjects at 3T, and 19 patients and
Wednesday, January 10, 2018 -- Cognitive challenges may occur in ALS due to the loss of synapses in the brain and therefore, may not occur indirectly due to the loss of neurons.
Tuesday, January 09, 2018 -- Neurodegeneration in ALS/FTD may be caused by TDP-43 aggregation in the cytoplasm, causing cellular traffic jams. The trial drug can sequester TDP-43.
Friday, January 05, 2018 -- Pfizer and Sangamo plan to develop a potential gene therapy for C9orf72 ALS that aims to protect motor neurons by reducing levels of repeat-rich RNAs.
Thursday, January 04, 2018 -- ALS is a debilitating and ultimately deadly neural disease that has few treatments and no cure.
Thursday, January 04, 2018 -- Patients older than 65 were more likely to have steeper declines in slow vital capacity.
Thursday, January 04, 2018 -- Pfizer and Sangamo Therapeutics are linking arms to develop a potential gene therapy to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).
Wednesday, January 03, 2018 -- (Reuters) - Sangamo Therapeutics Inc and Pfizer Inc said on Wednesday they would work together to develop a gene therapy to treat ALS, a disease that affects nerve cells in the brain and the spinal cord.
Tuesday, December 26, 2017 -- Scientists have revealed more details of the molecular mechanism behind neuronal cell death in amyotrophic lateral sclerosis (ALS), a step forward to find ways to control progression of the disease.
Friday, December 22, 2017 -- Reducing SOD1 in the CNS using CRISPR/Cas9 genome engineering delayed disease onset, improved motor function, and extended survival in a mouse model of SOD1 ALS.
Friday, December 22, 2017 -- In April, the department opened the petition process to allow patients, physicians and advanced practice registered nurses to petition the DOH to add new conditions to its list.
Thursday, December 21, 2017 -- The gene-editing tool was effective in disabling a defective gene responsible for some forms of amyotrophic lateral sclerosis.
Wednesday, December 20, 2017 -- Amyotrophic lateral sclerosis (ALS) is a fatal and incurable neurodegenerative disease characterized by the progressive loss of motor neurons in the spinal cord and brain. In particular, autosomal dominant mutations in the superoxide dismutase 1 (SOD1) gene are responsible for ~20% of all familial ALS cases. The clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated (Cas9) genome editing system holds the potential to treat autosomal dominant disorders by facilitating the introduction of frameshift-induced mutations that can disable mutant gene function. We demonstrate that CRISPR-Cas9 can be harnessed to disrupt mutant SOD1 expression in the G93A-SOD1 mouse model of ALS following in vivo delivery using an adeno-associated virus vector. Genome editing reduced mutant SOD1 protein by >2.5-fold in the lumbar and
Wednesday, December 20, 2017 -- An emerging mouse model may help scientists identify early changes that occur in ALS that could be targeted in the disease.
Friday, December 08, 2017 -- Previously Announced Results from Phase 3 Clinical Trial of Tirasemtiv Shared with ALS Community VITALITY-ALS Did Not Meet Primary or Secondary Endpoints Trial Informs Development of Next Generation Drug Candidate ...
Friday, December 08, 2017 -- University of Michigan-led research brings scientists one step closer to understanding the development of neurodegenerative disorders such as ALS.
Thursday, December 07, 2017 -- (MENAFN Editorial) LA JOLLA, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:) and the JASDAQ Mar...
Tuesday, December 05, 2017 -- Researchers presented new ALS approaches beginning to emerge and explored repurposing investigational therapies at SfN 2017 in Washington, DC.